Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gaofeng Li

Showing results (141-150 of 167) with videos related to

Pageof 17
Sort By:
Translational Cancer Research|February 4, 2022
Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A)Lan Wang, Xin Wang, Xuejiao Ren, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 14, 2024
Postoperative chemoradiotherapy with capecitabine and oxaliplatin <i>vs.</i> capecitabine for pathological stage N2 rectal cancerNing Li, Yuan Zhu, Luying Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 13, 2025
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancerHai-Yan Tu, Chun Chen, Chang Chen, et al.
Frontiers in Oncology|March 15, 2021
Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative GroupWeiping Liu, Yong Yang, Shunan Qi, et al.
The Oncologist|August 15, 2019
An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and ImmunotherapiesJingyu Cao, Lijuan Chen, Heng Li, et al.
Frontiers in Oncology|October 30, 2020
Stage III Esophageal Squamous Cell Carcinoma Patients With Three-Dimensional Conformal or Intensity-Modulated Radiotherapy: A Multicenter Retrospective StudyQin Qin, Xiaolin Ge, Xin Wang, et al.
BMJ (Clinical Research Ed.)|April 20, 2022
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trialZhihao Lu, Junye Wang, Yongqian Shu, et al.
Acta Oncologica (Stockholm, Sweden)|April 1, 2021
Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG SurveyChen Li, Xin Wang, Lan Wang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 7, 2024
Multidisciplinary team quality improves the survival outcomes of locally advanced rectal cancer patients: A post hoc analysis of the STELLAR trialHuiying Ma, Haoyue Li, Tongzhen Xu, et al.
Therapeutic Advances in Medical Oncology|November 3, 2022
Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysisWeiming Han, Lan Wang, Chen Li, et al.
Pageof 17

Showing results (141-150 of 167) with videos related to

Sort By:
Pageof 17
Translational Cancer Research|February 4, 2022
Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A)Lan Wang, Xin Wang, Xuejiao Ren, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 14, 2024
Postoperative chemoradiotherapy with capecitabine and oxaliplatin <i>vs.</i> capecitabine for pathological stage N2 rectal cancerNing Li, Yuan Zhu, Luying Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 13, 2025
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancerHai-Yan Tu, Chun Chen, Chang Chen, et al.
Frontiers in Oncology|March 15, 2021
Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative GroupWeiping Liu, Yong Yang, Shunan Qi, et al.
The Oncologist|August 15, 2019
An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and ImmunotherapiesJingyu Cao, Lijuan Chen, Heng Li, et al.
Frontiers in Oncology|October 30, 2020
Stage III Esophageal Squamous Cell Carcinoma Patients With Three-Dimensional Conformal or Intensity-Modulated Radiotherapy: A Multicenter Retrospective StudyQin Qin, Xiaolin Ge, Xin Wang, et al.
BMJ (Clinical Research Ed.)|April 20, 2022
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trialZhihao Lu, Junye Wang, Yongqian Shu, et al.
Acta Oncologica (Stockholm, Sweden)|April 1, 2021
Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG SurveyChen Li, Xin Wang, Lan Wang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 7, 2024
Multidisciplinary team quality improves the survival outcomes of locally advanced rectal cancer patients: A post hoc analysis of the STELLAR trialHuiying Ma, Haoyue Li, Tongzhen Xu, et al.
Therapeutic Advances in Medical Oncology|November 3, 2022
Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysisWeiming Han, Lan Wang, Chen Li, et al.
Pageof 17